- Home
- AORT vs ELVN Comparison
AORT vs ELVN Comparison
Compare AORT & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AORT
- ELVN
- Stock Information
- Founded
- AORT 1984
- ELVN 2016
- Country
- AORT United States
- ELVN United States
- Employees
- AORT N/A
- ELVN N/A
- Industry
- AORT Medical/Dental Instruments
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- AORT Health Care
- ELVN Health Care
- Exchange
- AORT Nasdaq
- ELVN Nasdaq
- Market Cap
- AORT 1.2B
- ELVN 1.0B
- IPO Year
- AORT 1993
- ELVN 2020
- Fundamental
- Price
- AORT $30.98
- ELVN $21.60
- Analyst Decision
- AORT Strong Buy
- ELVN Strong Buy
- Analyst Count
- AORT 5
- ELVN 5
- Target Price
- AORT $31.80
- ELVN $37.80
- AVG Volume (30 Days)
- AORT 351.8K
- ELVN 269.1K
- Earning Date
- AORT 02-13-2025
- ELVN 03-13-2025
- Dividend Yield
- AORT N/A
- ELVN N/A
- EPS Growth
- AORT N/A
- ELVN N/A
- EPS
- AORT N/A
- ELVN N/A
- Revenue
- AORT $384,899,000.00
- ELVN N/A
- Revenue This Year
- AORT $12.95
- ELVN N/A
- Revenue Next Year
- AORT $9.76
- ELVN N/A
- P/E Ratio
- AORT N/A
- ELVN N/A
- Revenue Growth
- AORT 13.29
- ELVN N/A
- 52 Week Low
- AORT $16.48
- ELVN $10.90
- 52 Week High
- AORT $32.33
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- AORT 57.65
- ELVN 47.03
- Support Level
- AORT $30.13
- ELVN $20.40
- Resistance Level
- AORT $32.18
- ELVN $22.42
- Average True Range (ATR)
- AORT 1.06
- ELVN 1.25
- MACD
- AORT -0.03
- ELVN 0.06
- Stochastic Oscillator
- AORT 46.43
- ELVN 59.59
About AORT Artivion Inc.
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.